These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26254276)

  • 41. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy.
    Hansen HP; Rossing P; Tarnow L; Nielsen FS; Jensen BR; Parving HH
    Kidney Int; 1995 Jun; 47(6):1726-31. PubMed ID: 7643542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
    Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
    Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
    Sica DA
    Methodist Debakey Cardiovasc J; 2015; 11(4):235-9. PubMed ID: 27057293
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.
    Zhao D; Liu H; Dong P; Zhao J
    Int J Cardiol; 2017 Apr; 233():113-117. PubMed ID: 28089457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R; Rossignol P; Garza D; Mayo MR; Warren S; Arthur S; Romero A; White WB; Williams B
    Am J Nephrol; 2018; 48(3):172-180. PubMed ID: 30176673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
    Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.
    Liu L; Xu B; Ju Y
    Clin Exp Hypertens; 2017; 39(3):257-263. PubMed ID: 28448185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Dojki FK; Bakris G
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):368-374. PubMed ID: 28771453
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes.
    Lin M; Heizati M; Wang L; Nurula M; Yang Z; Wang Z; Abudoyreyimu R; Wu Z; Li N
    Blood Press; 2021 Jun; 30(3):145-153. PubMed ID: 33682538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy.
    Takenaka T; Nobe K; Okayama M; Kojima E; Nodaira Y; Sueyoshi K; Hoshi H; Watanabe Y; Takane H; Suzuki H
    Clin Exp Hypertens; 2012; 34(4):243-8. PubMed ID: 22559034
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
    Oiwa A; Hiwatashi D; Takeda T; Miyamoto T; Kawata I; Koinuma M; Yamazaki M; Komatsu M
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2203-2210. PubMed ID: 36916985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.
    Currie G; Taylor AH; Fujita T; Ohtsu H; Lindhardt M; Rossing P; Boesby L; Edwards NC; Ferro CJ; Townend JN; van den Meiracker AH; Saklayen MG; Oveisi S; Jardine AG; Delles C; Preiss DJ; Mark PB
    BMC Nephrol; 2016 Sep; 17(1):127. PubMed ID: 27609359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.